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Introduction 
Since the time insulin was discovered, it has been of tremendous use to mankind in the 
treatment of morbid condition of diabetes [1, 2]. However, the role of insulin and insulin 
like growth factors (IGFs) is little understood while studying other pathological conditions 
of the body [3]. In recent years, there have been a number of studies which discuss the 
role of insulin and insulin like growth factors in other pathological ailments besides 
diabetes mellitus (DM) [4, 5, 6]. Though, a clear understanding of the mechanism of action 
and human clinical trials are still lacking. This brief review discusses the possible potential 
benefits of insulin and IGFs in treating various ailments besides diabetes. 
Insulin is secreted by pancreas and allows the body to utilize glucose from carbohydrates 
from the food that is consumed. It helps to prevent hyper or hypoglycaemia in body. After 
the food is consumed, the blood sugar rises and beta cells in pancreas secrete insulin into 
the blood stream. This hormone then attaches and signals cells to absorb sugar from 
bloodstream [5, 7]. 
Insulin like growth factors have structure similar to insulin [8, 9]. Though they are not 
secreted by beta cells of pancreas and their origin is limited to liver, they have shown to 
perform similar functions like insulin in various in-vitro models. 
Insulin like Growth Factors I and II 
IGFI is the mediator of growth hormone (GH) which is secreted from the anterior pituitary. 
GH stimulates liver to secrete IGF I which enhances body growth in muscle, cartilage, 
bones, nerves and lungs. IGFII has the effect in growth promotion during the gestation 
period. 
The structure of insulin and insulin like growth factor 1 and II is almost similar and these 
drugs have been shown to be interchangeable in performing various activities in in-vitro 
conditions. 
Role of Insulin in Diabetes 
The role of insulin in Diabetes Mellitus is well known. Insulin is secreted by the beta cells 
of pancreas and helps in regularizing the sugar levels in body. After the food is eaten, 
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hormone and its future prospects. 
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insulin is released by pancreas which allows the body to utilize 
glucose from the carbohydrates. It thus helps to prevent hypo 
or hyperglycaemia [1]. This is the most widely used method  
Role of Insulin and IGFs in Vascular Restenosis 
An important finding in the recent studies is the role of insulin 
and insulin like growth factors in preventing vascular restenosis 
after angioplasty. It is well known that a majority of patients 
undergo re-stenosis after the primary angioplasty procedures 
within 6 months of the treatment [10]. A number of 
laboratories have been working to understand the mechanism 
for the same. The restenosis of vessels has been attributed to 
two factors; increased smooth muscle cell hyperplasia and 
decreased adaptive vessel remodelling [11]. 
Though insulin has little effect in reducing the smooth muscle 
cell hyperplasia, it has been shown to cause increased vessel 
diameter and adaptive remodelling in vessels. In a recent 
patent, it has been shown that insulin along with connective 
tissue growth factor (CTGF) causes overall expansion of vessel 
size without the risk of aneurysm [12]. 
In another study, it has been shown that IGFII interacts with 
CTGF and leads to stimulation of a cascade that causes adaptive 
remodelling [4]. As per their study, it is the differential 
secretion of collagen III versus collagen I which is responsible 
for elasticity of the vessels. Since collagen I is more rigid, it leads 
to vessel constriction whereas collagen III is responsible for 
adaptive remodelling due to its elasticity [4]. 
In another in-vitro study, it has been shown that TGF beta and 
Smad3 treated smooth muscle cells (in vitro model for vascular 
injury) lead to increased secretion of CTGF and IGFII from 
vascular smooth muscle cells which in-turn stimulated collagen 
III more than Collagen I from vascular fibroblasts thus leading 
to adaptive vessel remodelling [4, 10]. 
Though the exact interaction of connective tissue growth factor 
and insulin like growth factor is little understood, a few studies 
have laid emphasis on the mechanism. It is believed that CTGF 
has a number of domains for Insulin like growth factor I/II and 
the complex activates after the attachment (figure 1). The 
domain then starts a cascade of events which leads to collagen 
synthesis. 
Clinical trials are being done to validate the role of insulin and 
insulin like growth factors in vascular stenosis. 
Role of Insulin and IGFs in fibrosis 
An interesting finding about insulin’s role in vascular stenosis 
has come up after its interaction with connective tissue growth 
factor was notices. Sharing the similar structure as insulin like 
growth factors, insulin can bind with the domain site of CTGF 
and activate the cascade for increased synthesis of fibrous 
tissues (Fig 1). This may help in increased wound healing and 
faster growth of skin. A property which can be of tremendous 
use in defence and plastic surgery [10]. 
 
Figure 1. Possible pathway of fibrosis by interaction of IGF and CTGF 
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TGF beta (injury) leads to activation of SMAD3 in smooth 
muscle cells which leads to the secretion of various growth 
factors from the SMCs. The growth factors interact and activate 
CTGF after binding to the respective domain. The activated 
CTGF acts on fibroblasts and secretion of collagen takes place 
(Figure 1). 
Role of insulin in spinal injuries  
A recently conducted study has even discussed the role of 
insulin like growth factors in acute spinal cord injury. After an 
acute injury to spinal cord, a subacute inflammatory process 
usually begins. The repair and modulation of the spinal cord 
begins under the mediation of growth factors like IGF1 and II. 
These growth factors have been shown to be of 
neuroprotective nature and its role has not only been 
confirmed in animals but also humans. In another study 
conducted on 45 individuals, the levels of insulin like growth 
factors were significantly high in blood after acute spinal cord 
injury. These findings may throw a light on the use of insulin or 
insulin like growth factors in spinal cord regeneration after an 
acute spinal cord injury. IGFs may hold future in acute spinal 
injuries with limb paresis and replace steroids as the drug of 
choice in golden period [11].  
Insulin and Insulin like growth factors definitely hold a lot of 
promise for future. Their role in liver dysfunctions and other 
ailments is still being explored [13]. A number of studies are 
thus warranted to explore the potential that these agents hold. 
This brief communication is just to highlight a few new 
explorations being done by laboratories all around the world. 
More studies are thus warranted. 
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